Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug

CEO Shawn Singh discusses path forward for fasedienol (PH94B) using the classic LSAS primary endpoint in next clinical trial. Pherine nasal spray candidate failed to meet the primary endpoint (the patient-reported SUDS) in its first pivotal Phase III study, whose design was constrained by the Covid pandemic.